Opendata, web and dolomites

LAA-START SIGNED

Left Atrial Appendage Electrical Isolation via Bio-photonic Optical Confirmation to Treat Persistent Atrial Fibrillation

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 LAA-START project word cloud

Explore the words cloud of the LAA-START project. It provides you a very rough idea of what is the project "LAA-START" about.

left    catheter    cardiac    symptomatic    occlusion    health    incapable    medication    destroys    fibrillation    flow    fitting    appendage    aurigen    medical    filter    ablation    line    permanently    tissue    efficacy    services    mechanically    blood    works    isolates    healthcare    13    million    isolation    abnormal    hours    paf    first    resistant    risk    time    5bn    patients    irregular    q3    fti    financially    doubles    amounting    implants    2020    opportunity    rates    procedure    germany    stroke    classified    clinical    france    therapy    laa    fda    persistent    complete    certification    shot    italy    ce    entering    implant    surgical    market    human    heart    wasted    minimally    72    markets    opening    regulatory    prevent    electrical    too    stream    treating    redo    electrically    fit    arrhythmia    invasive    enter    muscle    contraction    billion    causing    uk    approximately    device    af    surgery    shut    heartbeat    clots    initial    data    pulses    safety    caused    atrial    doubled    total    30    least   

Project "LAA-START" data sheet

The following table provides information about the project.

Coordinator
AURIGEN MEDICAL LIMITED 

Organization address
address: 18 CHURCHWELL SQUARE
city: DUBLIN
postcode: DUBLIN 13
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Total cost 5˙012˙590 €
 EC max contribution 2˙999˙998 € (60%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-EIC-FTI-2018-2020
 Funding Scheme IA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2020-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AURIGEN MEDICAL LIMITED IE (DUBLIN) coordinator 1˙115˙458.00
2    TELEFLEX MEDICAL EUROPE LIMITED IE (ATHLONE CO. WESTMEATH) participant 953˙470.00
3    UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK IE (Cork) participant 516˙948.00
4    MEDIBRANE LTD IL (ROSH HAAYIN) participant 334˙600.00
5    CESKE VYSOKE UCENI TECHNICKE V PRAZE CZ (PRAHA) participant 79˙522.00

Map

 Project objective

Atrial Fibrillation (AF) is an irregular heartbeat caused by abnormal electrical activity in the heart, that can lead to blood clots with high risk of stroke and heart failure. There are 10.7 million AF patients across Europe and the US, 3.6 million are classified as having Persistent AF (PAF), they are highly symptomatic and medication resistant. Surgical electrical therapy (catheter ablation) destroys heart tissue causing the abnormal electrical pulses. For PAF patients, this works only 30% of the time. Approximately 72% of PAF patients require at least one redo procedure, amounting to €13.5 billion in wasted healthcare costs. Success rates are doubled if electrical activity in a part of the heart “the Left Atrial Appendage” (LAA), is shut down. But this increases stroke risk from blood clots as the LAA is now incapable of muscle contraction to maintain blood flow. LAA implants, “occlusion devices” fit across the opening of the LAA to filter the blood and prevent clots from entering the blood stream. However, fitting an occlusion device during the same procedure as LAA electrical isolation doubles procedure time (to 7 hours) making it non-financially viable for health services and too high risk for patients. AuriGen Medical have developed a unique, minimally invasive cardiac implant which permanently electrically and mechanically isolates the LAA in a one-shot procedure: treating both the stroke and arrhythmia risk associated with PAF with no increase in surgery time. This multi-partner FTI project will complete product development in line with the regulatory development pathway for medical devices for first in human safety and efficacy clinical studies required for CE certification and contributing to FDA clinical data requirements. The total market opportunity is $5bn/yr market opportunity across the EU and US. AuriGen will enter the market directly in the initial target European markets (Germany, France, Italy and UK) during Q3 2020.

 Deliverables

List of deliverables.
Clinical Affairs Director Appointed Other 2020-04-02 09:09:54
Biostatistician Appointed Other 2020-04-02 09:10:11
Manufacturing Engineer Appointed Other 2020-04-02 09:10:03

Take a look to the deliverables list in detail:  detailed list of LAA-START deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LAA-START" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LAA-START" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.1.)

GoSafe (2019)

Restoring complete sensory ability for natural walking of amputees

Read More  

Mag-ID (2019)

Magnetic identification

Read More  

GIoT (2019)

Nano-satellites based Global Infrastructure to Enable IoT/M2M Networks - GIoT (Global IoT)

Read More